← MannKind overview

MannKind vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

MannKind Corp (MNKD)

Q3 2026
▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

  • Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.

    This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.

  • Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.

    This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.

  • $50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.

    This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.

  • Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.

    This is a new product approval that diversifies revenue and has already started contributing to growth.

  • Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.

    This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.

  • Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.

    This earnings report confirms strong financial performance and execution, which supports the stock's value.

July 2026
▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

  • Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.

    This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.

  • Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.

    This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.

  • $50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.

    This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.

  • Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.

    This is a new product approval that diversifies revenue and has already started contributing to growth.

  • Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.

    This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.

  • Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.

    This earnings report confirms strong financial performance and execution, which supports the stock's value.

Latest
▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

  • Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.

    This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.

  • Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.

    This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.

  • $50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.

    This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.

  • Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.

    This is a new product approval that diversifies revenue and has already started contributing to growth.

  • Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.

    This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.

  • Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.

    This earnings report confirms strong financial performance and execution, which supports the stock's value.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.